June 24, 2008
NanoGuardian’s Client Wins Approval for NanoEncryption Technology
NanoGuardian, a division of NanoInk, has announced that the FDA has issued approval to a NanoGuardian client to use NanoGuardian's NanoEncryption technology as an on-dosage, brand protection technology.
NanoGuardian said that its NanoEncryption technology provides pharmaceutical manufacturers with true forensic, multi-layered, authentication and tracing brand protection at the individual dosage level.
James Hussey, CEO of NanoInk, said: "FDA approval of our NanoEncryption technology is an important milestone for public health and the continued fight to secure the pharmaceutical supply chain."